Hofseth Biocare ASA : Approval of prospectus

The Norwegian Financial Supervisory Authority has approved the prospectus dated 16 May 2014 in connection with the listing of 20,000,000 new shares in Hofseth BioCare ASA on Oslo Axess.

 

The prospectus will be made publicly available at the following addresses:
- Hofseth BioCare ASA, Molovegen 6, 6000 Ålesund, Norge. Tlf.: +47 70 10 26 30
- Carnegie AS, Grundingen 2, 0250 Oslo, Norge. Tlf.: +47 22 00 93 00
- Swedbank Norge, Filipstad Brygge 1, 0252 Oslo, Norge. Tlf.: +47 04010

 

The prospectus will also be available at the following websites:
- Hofseth BioCare, www.hofsethbiocare.no
- Swedbank Norge, www.swedbank.no
- Carnegie AS, www.carnegie.no

 

For further information, please contact:
Jon Olav Ødegård, CEO of Hofseth BioCare ASA
Phone: +47 936 32 966
E-mail: jon.olav.odegard@hofsethbiocare.no

 

Øystein Omvik, CFO of Hofseth BioCare ASA
Phone: +47 936 99 400
E-mail: oystein.omvik@hofsethbiocare.no

 

About Hofseth BioCare:
Hofseth BioCare is a Norwegian biomarine company with the key objective to provide high value added biomarine ingredients for human applications. The Company is founded on the core value of sustainability and optimal use of natural resources. Through innovative production technology and logistics, Hofseth BioCare is able to preserve the quality of protein, calcium and oil extracted from fish off-cuts. Products that previously could only be used as animal feed can now be made suitable for human consumption. HBCs objective is thus to contribute to efficient use of marine resources and entering the higher profit market of quality ingredients for human applications.

 

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.